167 related articles for article (PubMed ID: 36175619)
41. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
[TBL] [Abstract][Full Text] [Related]
42. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
43. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
44. Molecular-genetic diagnostics of von Hippel-Lindau syndrome (VHL) in Bulgaria: first complex mutation event in the VHL gene.
Glushkova M; Dimova P; Yordanova I; Todorov T; Tourtourikov I; Mitev V; Todorova A
Int J Neurosci; 2018 Feb; 128(2):117-124. PubMed ID: 28849724
[TBL] [Abstract][Full Text] [Related]
45. Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors.
Minervini G; Quaglia F; Tabaro F; Tosatto SCE
PLoS Comput Biol; 2019 Apr; 15(4):e1006478. PubMed ID: 30943211
[TBL] [Abstract][Full Text] [Related]
46. VHL Germline Mutations in Argentinian Patients with Clinical Diagnoses or Single Typical Manifestations of Type 1 von Hippel-Lindau Disease.
Mathó C; Sansó G; Diez B; Barontini M; Pennisi PA
Genet Test Mol Biomarkers; 2016 Dec; 20(12):771-776. PubMed ID: 27617348
[TBL] [Abstract][Full Text] [Related]
47. [Genetic analysis of a family with Von Hippel-Lindau syndrome].
Lafuente-Sanchis A; Cuevas JM; Alemany P; Cremades A; Zúñiga Á
Rev Esp Patol; 2017; 50(1):64-67. PubMed ID: 29179968
[TBL] [Abstract][Full Text] [Related]
48. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
49. Genetic characterization and protein stability analysis of a Chinese family with Von Hippel-Lindau disease.
Gao Y; Huang YP; Tu XA; Luo DS; Wang DH; Qiu SP; Xiang P; Li WQ; Jan R; Zhang YY; Sun XZ; Deng CH
Chin Med J (Engl); 2013; 126(19):3690-3. PubMed ID: 24112165
[TBL] [Abstract][Full Text] [Related]
50. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
[TBL] [Abstract][Full Text] [Related]
51. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
52. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
53. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
54. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.
Heo SJ; Lee CK; Hahn KY; Kim G; Hur H; Choi SH; Han KS; Cho A; Jung M
Cancer Res Treat; 2016 Jan; 48(1):409-14. PubMed ID: 25715769
[TBL] [Abstract][Full Text] [Related]
55. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
Lolkema MP; Mans DA; Ulfman LH; Volpi S; Voest EE; Giles RH
Eur J Hum Genet; 2008 Jan; 16(1):73-8. PubMed ID: 17912253
[TBL] [Abstract][Full Text] [Related]
56. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation.
Schmidt L; Li F; Brown RS; Berg S; Chen F; Wei MH; Tory K; Lerman I; Zbar B
Cancer J Sci Am; 1995; 1(3):191-5. PubMed ID: 9166475
[TBL] [Abstract][Full Text] [Related]
58. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
59. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
Ma X; Yang K; Lindblad P; Egevad L; Hemminki K
Oncogene; 2001 Aug; 20(38):5393-400. PubMed ID: 11536052
[TBL] [Abstract][Full Text] [Related]
60. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
